How BLD Helps
S-217622 - Creating a Myth for COVID-19 Monotherapy?
10 February 2022
6-Chloro-2-methyl-2H-indazol-5-amine
3-(Chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride
1-(Bromomethyl)-2,4,5-trifluorobenzene
3-(tert-Butyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione
S-217622, a therapeutic drug for COVID-19, is a 3CL protease inhibitor created through joint research between Hokkaido University and Shionogi. The results up to day 6 of the Phase 2a part of a Phase 2/3 clinical trial of S-217622 showed a rapid virus reduction effect without high-grade or serious adverse events observed. Different from the Pfizer's Paxlovid, S-217622 is expected to achieve monotherapy and get rid of dependence on CYP450 inhibitors.
S-217622
®